Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.72 USD | +1.00% | -6.81% | -11.48% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.42B |
---|---|---|---|---|---|
Net income 2024 * | -235M | Net income 2025 * | -271M | EV / Sales 2024 * | - |
Net cash position 2024 * | 388M | Net cash position 2025 * | 282M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.08
x | P/E ratio 2025 * |
-4.51
x | Employees | 56 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.16% |
Latest transcript on Akero Therapeutics, Inc.
1 day | -5.05% | ||
1 week | -6.09% | ||
Current month | -18.80% | ||
1 month | -23.58% | ||
3 months | -4.91% | ||
6 months | +49.38% | ||
Current year | -12.16% |
Managers | Title | Age | Since |
---|---|---|---|
Jonathan Young
FOU | Founder | 54 | 17-03-31 |
Timothy Rolph
FOU | Founder | 70 | 17-03-31 |
Andrew Cheng
CEO | Chief Executive Officer | 57 | 18-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Seth Harrison
BRD | Director/Board Member | 63 | 16-12-31 |
Jane Henderson
BRD | Director/Board Member | 59 | 19-04-22 |
Mark Iwicki
CHM | Chairman | 57 | 18-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.12% | 237 M€ | -1.30% | - | |
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 20.67 | +0.78% | 229 869 |
24-04-18 | 20.51 | -5.05% | 760,868 |
24-04-17 | 21.6 | -0.87% | 823,317 |
24-04-16 | 21.79 | +0.32% | 940,162 |
24-04-15 | 21.72 | -2.07% | 757,568 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.16% | 1.42B | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.43% | 21.66B | |
-18.35% | 20.77B | |
-8.65% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- AKRO Stock